个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Complete dissection of right paratracheal lymph nodes (stations 2R and 4R) is critical to improve the prognosis of lung cancer patients: A retrospective cohort study

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Zhao Kejia[1,2] * ; Mei Jiandong[1,2] ; Hu Binbin[3] ; Guo Chenglin[1,2] ; Wei Shiyou[1,2] ; Yang Xudong[4] ; Yang Zhenyu[1,2] ; Zhang Jian[1,2] ; Ku Yin[1,2] ; Zheng Yao[1,2] ; Wu Di[1,2] ; Li Shasha[1,2] ; Mao Yonghong[1,2] ; Ding Yu[1,2] ; Liu Lunxu[1,2,*1] ;
机构： [1]Department of Thoracic Surgery and Institute of Thoracic Oncology, West China Hospital, Sichuan University, Chengdu, China. [2]Western China Collaborative Innovation Center for Early Diagnosis and Multidisciplinary Therapy of Lung Cancer, Chengdu, China. [3]Department of Radiation Oncology, West China Hospital, Sichuan University, Chengdu, China. [4]Department of Thoracic Surgery, The First Affiliated Hospital of Kunming Medical University, Kunming, China.
出处：
DOI： 10.1111/1759-7714.15122
ISSN：

关键词： 2R lymph node 4R lymph node non-small cell lung cancer prognosis right paratracheal node dissection

摘要：
The optimal extent of mediastinal lymph node dissection is still under debate. This study aimed to investigate the prognostic impact of complete dissection of right paratracheal lymph nodes (LNs) in right-sided non-small cell lung cancer (NSCLC) and evaluate the potential patient population who will particularly benefit from right paratracheal node dissection (RPND).Between January 2009 and December 2019, we retrospectively reviewed 2650 patients with primary right-sided NSCLC who underwent pulmonary surgery with lymphadenectomy in the Western China Lung Cancer Database. A total of 2447 patients received both 2R and 4R LNs dissection (complete RPND group), 162 patients received only 2R or 4R LNs dissection (incomplete RPND group), and 41 patients received neither 2R nor 4R LNs dissection (no RPND group). Overall survival (OS) was analyzed.The metastasis rates in stations 2R and 4R were 6.5% and 8.0%, respectively. In stage N2 patients, the frequency of involvement of stations 2R/4R was 74.8%. The complete RPND group had a significantly better survival than the incomplete and no RPND group (5-year OS, 79.5% vs. 72.7% vs. 65.5%; p < 0.001). In the multivariate analysis, status of RPND (incomplete RPND vs. complete RPND: HR 1.45, 95% CI: 1.10-1.90; p = 0.009; no RPND vs. complete RPND: HR 2.25, 95% CI: 1.37 to 3.69; p = 0.001), age, gender, tumor size, histological type, pTNM stage, pT stage, pN stage, and adjuvant treatment were independent factors for OS.Complete RPND brings survival benefits to patients with right-sided NSCLC. We suggest complete RPND as a standard procedure for patients with right-sided NSCLC.© 2023 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.

基金：
China Postdoctoral Science Foundation, Grant/Award Number: 2021M692268; National Natural Science Foundation of China, Grant/Award Number: 82103251; The 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University, Grant/Award Numbers: ZYGD18021, ZYJC18009
语种：
外文
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2023]版：
大类 | 3 区 医学
小类 | 4 区 肿瘤学 4 区 呼吸系统
最新[2023]版：
大类 | 3 区 医学
小类 | 4 区 肿瘤学 4 区 呼吸系统
JCR分区：
出版当年[2023]版：
Q2 RESPIRATORY SYSTEM Q3 ONCOLOGY
最新[2023]版：
Q2 RESPIRATORY SYSTEM Q3 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版]

第一作者：
第一作者机构： [1]Department of Thoracic Surgery and Institute of Thoracic Oncology, West China Hospital, Sichuan University, Chengdu, China. [2]Western China Collaborative Innovation Center for Early Diagnosis and Multidisciplinary Therapy of Lung Cancer, Chengdu, China.
通讯作者：
通讯机构： [1]Department of Thoracic Surgery and Institute of Thoracic Oncology, West China Hospital, Sichuan University, Chengdu, China. [2]Western China Collaborative Innovation Center for Early Diagnosis and Multidisciplinary Therapy of Lung Cancer, Chengdu, China. [*1]No. 37, Guoxue Alley, Chengdu, Sichuan, 610041, China.
推荐引用方式(GB/T 7714)：
Zhao Kejia,Mei Jiandong,Hu Binbin,et al.Complete dissection of right paratracheal lymph nodes (stations 2R and 4R) is critical to improve the prognosis of lung cancer patients: A retrospective cohort study[J].THORACIC CANCER.2023,14(33):3309-3316.doi:10.1111/1759-7714.15122.
APA：
Zhao Kejia,Mei Jiandong,Hu Binbin,Guo Chenglin,Wei Shiyou...&Liu Lunxu.(2023).Complete dissection of right paratracheal lymph nodes (stations 2R and 4R) is critical to improve the prognosis of lung cancer patients: A retrospective cohort study.THORACIC CANCER,14,(33)
MLA：
Zhao Kejia,et al."Complete dissection of right paratracheal lymph nodes (stations 2R and 4R) is critical to improve the prognosis of lung cancer patients: A retrospective cohort study".THORACIC CANCER 14..33(2023):3309-3316

相关文献

[1]An integrated bioinformatics approach to early diagnosis, prognosis and therapeutics of non-small-cell lung cancer [2]Overexpression of HN1L promotes cell malignant proliferation in non-small cell lung cancer [3]Factors That Improve Chest Computed Tomography-Defined Sarcopenia Prognosis in Advanced Non-Small Cell Lung Cancer. [4]Reduced circulating exosomal miR-382 predicts unfavorable outcome in non-small cell lung cancer. [5]MAP kinase-interacting serine/threonine kinase 2 promotes proliferation, metastasis, and predicts poor prognosis in non-small cell lung cancer [6]AXL-GAS6 expression can predict for adverse prognosis in non-small cell lung cancer with brain metastases [7]Mining expression and prognosis of topoisomerase isoforms in non-small-cell lung cancer by using Oncomine and Kaplan-Meier plotter [8]Cuproptosis-associated lncRNA impact prognosis in patients with non-small cell lung cancer co-infected with COVID-19 [9]Prognostic value of molecular events from negative surgical margin of non-small-cell lung cancer [10]Decreased complement 4d increases poor prognosis in patients with non-small cell lung cancer combined with gastrointestinal lymph node metastasis

资源点击量：52808 今日访问量：0 总访问量：4561 更新日期：2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号